CClinicalTrials.gg
CompletedNCT03079895Updated Mar 8, 2018

Thrive Care: Internet CBT for Depression

An interventional study of Thrive in Depression, sponsored by Kaiser Permanente. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-08.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This project will study the effectiveness of computerized cognitive behavioral therapy (CBT) in reducing depression symptoms. The design is a two-arm randomized controlled trial comparing (i) control arm, which is treatment as usual with (ii) treatment arm, which is treatment as usual plus computerized CBT. The primary outcome measure is change in depression symptom severity. The name of the computerized CBT program to be used in the study is Thrive.

Read the detailed description

Population:

  • As identified in Epic, Kaiser Permanente Southern California (KPSC) Fontana Family Medicine patients with a depression diagnosis recorded during the prior week (rolling basis).
  • Target study enrollment: 150 participants per arm (300 total)

Recruitment:

  • Kaiser Permanente (KP) will send eligible patients a postal letter inviting them to participate in study. Interested patients will be directed to the Enrollment/Assessment Website, a website to be developed by vendor Waypoint Health Innovations. The recruitment letter will contain (i) a description of the study, (ii) the web address for the Enrollment/Assessment Website, (iii) the patient's Study Identifier (ID).
  • Additionally, KP will send eligible patients for whom KP has an email address an email inviting them to participate in the study.

Screening and Enrollment (Enrollment/Assessment Website):

  • A patient interested in applying to the study will visit the Enrollment/Assessment Website and input his/her unique Study ID. The website will verify that the entered Study ID is on a pre-loaded list. If valid, the patient may continue to screening assessments.
  • Patient will complete the 9-item Patient Health Questionnaire (PHQ-9) depression symptom assessment. Patients with eligible PHQ-9 scores may continue to Informed Consent page.
  • The Informed Consent (IC) page will contain (i) the Informed Consent text including contact information for any questions patient may have; (ii) fields for first name, last name, date of birth, email address, and phone number; (iii) a check box labeled "I understand the above information and agree to participate..." (or similar); and (iv) a "submit" (or similar) button.
  • To enroll in the study, the patient must complete all fields, check the box, and click submit button. The website will validate that every field has been completed and that the phone number and email fields have the correct format (e.g. name@domain.com for the email field).
  • If all fields are complete, the website will store the Study ID, first name, last name, date of birth, email address, and phone number that patient entered into the website. They will be stored in an encrypted database for use by researchers.
  • Additionally, the website will store the complete Informed Consent page (including Informed Consent text, first name, last name, date of birth, email address, phone number, and checked box) in a single encrypted record, timestamp it, and place a digital certificate on it. The digital certificate will allow us to prove that no one tampered with any part of the IC document after the participant clicked submit.
  • The website automatically randomizes participants to treatment or control arm. Participants continue in website to baseline assessments.
  • After baseline assessments, control arm participants go to a page in the Enrollment/Assessment Website telling them to expect assessment again in 2 months, while treatment arm participants will be given instructions for enrolling in Thrive.
  • Researchers would have access to the completed IC forms to print and/or mail to patients who request a copy.
  • Weekly, KP research coordinator will review new participants' study ID, name, and date of birth (DOB) the participant entered to ensure they match KP records. Individuals who entered information that does not reasonably match KP records would be removed from the study.

Coaching:

  • KP will send each treatment arm participant four emails encouraging them to use Thrive, with the exception that the second email will be replaced by a phone call from KP for patients who have not achieved a minimum level of activity in Thrive at that point.

Endpoint and Follow-up Assessments:

  • KP will ask each study participant to visit Enrollment/Assessment Website 2 and 6 months after study enrollment to complete assessments.
02

Conditions studied

  • Depression

Keywords

  • Depression
  • internet
  • Cognitive Behavioral Therapy
  • CBT
  • computer
  • Primary Care
  • Psychiatry
  • treatment
  • self-help
  • managed care
03

In context

Depression

8,055 studies on the registry are indexed under Depression; 1,643 are open to participants now.

This study's enrollment of 304 is above the median of 84 across 6,718 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Per EPIC (or other system) records, clinical depression was addressed during the prior week by a KPSC Fontana Family Medicine physician , reflected by an ICD-9 or ICD-10 diagnosis of Depression, Major Depressive Disorder, Dysthymia, Adjustment Disorder with Depressed Mood, and Depression Not Otherwise Specified. This does not have to be the patient's first depression diagnosis.
  • Screening Patient Health Questionnaire (PHQ-9) score of ≥5 as measured in Assessment Website (see Section 4 for information on Assessment Website)

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis indicating any Schizophrenia spectrum or other psychotic disorder, any Neurocognitive disorder, Delirium, Bipolar disorder, Intellectual disability, or Personality disorder, or any active substance abuse, as defined by DSM-5
  • Member is not proficient in English
  • Member answered "more than half the days" or "nearly every day" on the Patient Health Questionnaire ninth item and did not subsequently answer (regarding suicidal ideations) "Yes" to the question "are you sure you can stay safe?"
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
304 participants (actual)

Study arms

  • No intervention
    Control Arm

    After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.

  • Experimental
    Intervention Arm

    After enrollment in the study, the subject will be granted 8 weeks of access to "Thrive", an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.

    Behavioral: Thrive

Interventions

  • BehavioralThrive

    Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.

    Also known as: Thrive for Depression

06

What researchers measure

Primary outcomes

  1. PHQ-9 score change

    Change in score on the 9-item Patient Health Questionnaire

    Time frame: 0-6 months after enrollment

Secondary outcomes

  1. GAD-7 score change

    Change in score on 7-item Generalized Anxiety Disorder scale

    Time frame: 0-6 months after enrollment

  2. Quality of Life change

    Change in subjective measure of subject's quality of life (based on Behavioral Risk Factor Surveillance System)

    Time frame: 0-6 months after enrollment

  3. Workplace productivity change

    Change in subjective measure of subject's workplace productivity (based on Behavioral Risk Factor Surveillance System)

    Time frame: 0-6 months after enrollment

  4. Medication adherence

    Measure of compliance with prescribed medications, based on a single item question

    Time frame: 0-6 months after enrollment

  5. Psychotherapy utilization

    Subjective measurement of whether or not the subject has received psychotherapy from a licensed provider

    Time frame: 12 months prior to enrollment, through 6 months after enrollment

  6. Psychiatric specialty utilization

    Subjective measurement of whether or not the subject has received treatment from a provider in the Department of Psychiatry

    Time frame: 0-6 months after enrollment

  7. Satisfaction with Thrive

    Subjective measurement of how satisfied patient was with the treatment intervention

    Time frame: 2 months after enrollment

  8. Satisfaction with Kaiser Permanente Southern California

    Subjective measurement of how satisfied patient was with their experience of care at Kaiser Permanente Southern California

    Time frame: 0-6 months after enrollment

  9. Thrive Adherence

    Percent enrolled in Thrive over total number invited, number of logins and lessons started

    Time frame: 0-2 months after enrollment

07

Study locations

1 site
  • Kaiser Fontana Medical Center
    Fontana, California 92335, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03079895
Lead sponsor
Kaiser Permanente
Responsible party
Sponsor
First posted
Mar 15, 2017
Start date
Apr 13, 2017
Primary completion
Dec 13, 2017
Completion
Dec 13, 2017
Last update
Mar 8, 2018

Study contacts

Roderick R Stuart, MD
principal investigator · Southern California Permanente Medical Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion